Key terms
About MDGL
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest MDGL news
May 15
5:31pm ET
Paulson buys Carrols, exits SSR Mining in Q1
May 15
8:08am ET
89bio price target lowered to $33 from $37 at Evercore ISI
May 15
8:06am ET
Akero Therapeutics price target lowered to $38 from $50 at Evercore ISI
May 13
8:01am ET
Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL), Akero Therapeutics (AKRO) and Madrigal Pharmaceuticals (MDGL)
May 10
8:13am ET
Madrigal Pharmaceuticals price target lowered to $200 from $270 at B. Riley
May 10
7:58am ET
Madrigal Pharmaceuticals (MDGL) Receives a Buy from Piper Sandler
May 10
1:18am ET
Buy Rating Affirmed for Madrigal Pharmaceuticals Amid Strong Start for Rezdiffra
May 09
1:20pm ET
Analysts Conflicted on These Healthcare Names: Madrigal Pharmaceuticals (MDGL) and Warby Parker (WRBY)
May 09
4:55am ET
Madrigal Pharmaceuticals management to meet with Oppenheimer
May 08
12:12pm ET
Madrigal price target lowered to $390 from $425 at H.C. Wainwright
May 08
6:55am ET
Madrigal Pharmaceuticals price target lowered to $381 from $397 at JMP Securities
May 07
9:15pm ET
Buy Rating Affirmed for Madrigal Pharmaceuticals Amid Promising Launch of First Approved NASH Treatment and Strong Market Positioning
May 07
8:53pm ET
Madrigal Pharmaceuticals price target lowered to $382 from $389 at Citi
May 07
4:52pm ET
Madrigal Pharmaceuticals’ Strategic Stock Sales Agreements
May 07
4:45pm ET
Buy Rating Affirmed for Madrigal Pharmaceuticals Amid Strong Rezdiffra Launch and Solid Financials
May 07
3:53pm ET
Madrigal Pharmaceuticals management to meet with Oppenheimer
Apr 30
6:53am ET
Biotech Sector: M&A Fuels Renewed Excitement
Apr 25
10:38am ET
Biotech Alert: Searches spiking for these stocks today
Apr 22
12:25pm ET
United Healthcare’s Favorable Insurance Coverage of Rezdiffra Boosts Madrigal Pharmaceuticals Buy Rating
Apr 22
12:20pm ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cardinal Health (CAH) and Madrigal Pharmaceuticals (MDGL)
Apr 22
12:18pm ET
United not requiring prior authorization for Madrigal drug, says JMP
Apr 22
10:04am ET
BofA starts Madrigal at Underperform amid Rezdiffra launch questions
Apr 22
6:12am ET
Madrigal Pharmaceuticals initiated with an Underperform at BofA
Apr 09
8:15pm ET
Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX) and Madrigal Pharmaceuticals (MDGL)
Mar 25
6:50am ET
Analysts Conflicted on These Healthcare Names: Masimo (MASI), ImmunityBio (IBRX) and Madrigal Pharmaceuticals (MDGL)
Mar 20
8:13am ET
Madrigal Pharmaceuticals price target raised to $405 from $325 at Evercore ISI
Mar 19
5:58am ET
Madrigal Pharmaceuticals 750K share Spot Secondary priced at $260.00
Mar 19
2:00am ET
Analysts Are Bullish on These Healthcare Stocks: Cullinan Management (CGEM), Gilead Sciences (GILD)
Mar 18
4:05pm ET
Madrigal Pharmaceuticals announces $500M common stock offering
Mar 18
11:03am ET
Biotech Alert: Searches spiking for these stocks today
Mar 15
10:26am ET
BofA says 89bio should trade with strength after ‘win for entire MASH space’
No recent press releases are available for MDGL
MDGL Financials
Key terms
Ad Feedback
MDGL Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
MDGL Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
